A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.
Steven O'Day
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Rene Gonzalez
Research Funding - Eisai
Kevin Kim
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Bartosz Chmielowski
Consultant or Advisory Role - Eisai
Richard Kefford
No relevant relationships to disclose
Georgina Long
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - Roche
Carmen Loquai
No relevant relationships to disclose
Charles Lance Cowey
Research Funding - Eisai
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; Oncoscience; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
John D. Hainsworth
No relevant relationships to disclose
Peter Hersey
No relevant relationships to disclose
Frances Boyle
No relevant relationships to disclose
T. R. Jeffry Evans
Research Funding - Eisai
Omid Hamid
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Nicole Meneses
Employment or Leadership Position - Eisai
Corina Andresen
Employment or Leadership Position - Eisai
Min Ren
Employment or Leadership Position - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Keith Flaherty
Consultant or Advisory Role - Eisai
Research Funding - Eisai